Recent Research Analysts’ Ratings Updates for Caris Life Sciences (CAI)

Several analysts have recently updated their ratings and price targets for Caris Life Sciences (NASDAQ: CAI):

• 2/27/2026 – Caris Life Sciences had its price target lowered by BTIG Research from $45.00 to $38.00. They now have a “buy” rating on the stock.
• 2/27/2026 – Caris Life Sciences had its price target raised by Robert W. Baird from $26.00 to $28.00. They now have an “outperform” rating on the stock.
• 2/21/2026 – Caris Life Sciences was downgraded by Wall Street Zen from “buy” to “hold”.
• 2/17/2026 – Caris Life Sciences is now covered by Robert W. Baird. They set an “outperform” rating and a $26.00 price target on the stock.
• 2/17/2026 – Caris Life Sciences is now covered by Robert W. Baird. They set an “outperform” rating and a $26.00 price target on the stock.
• 1/17/2026 – Caris Life Sciences was upgraded by Wall Street Zen from “hold” to “buy”.
• 1/5/2026 – Caris Life Sciences was given a new $38.00 price target by Evercore Inc.

Insider Activity at Caris Life Sciences

In related news, insider Luke Thomas Power sold 62,250 shares of Caris Life Sciences stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $26.58, for a total transaction of $1,654,605.00. Following the completion of the sale, the insider directly owned 99,571 shares of the company’s stock, valued at $2,646,597.18. The trade was a 38.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.